Michael Schuleit

Michael Schuleit currently serves as a Senior Investigator at Novartis Pharma AG, where he plays a pivotal role in advancing drug delivery technologies within a highly regulated GMP environment. His expertise spans the entire spectrum of preclinical science, from basic research to technical implementation, ensuring seamless analytical transfer activities to pharmaceutical manufacturing. In his leadership capacity, Michael oversees interdisciplinary R&D collaborations, fostering innovation across formulation development, biomaterials, and local drug delivery systems. His focus on lipid crystalline mesophases, biodegradable microparticles, and hydrogels positions him at the forefront of sustained drug release and long-acting injectable formulations, particularly for small molecules, peptides, and large hydrophilic macromolecules.

A key project under his direction involves the development of lipid-based formulations for long-acting injectables, where his deep understanding of colloid and surface science, tribology, and polymer analysis has been instrumental in optimizing drug stability, bioavailability, and controlled release profiles. Michael’s hands-on approach in troubleshooting complex formulation challenges, combined with his expertise in self-assembly structures and biomaterials, ensures robust technical solutions that meet regulatory standards. His leadership in formulation platform development has significantly contributed to Novartis’ pipeline of innovative therapeutics, especially in joint, tendon, and cartilage regeneration.

With a proven track record in project management and people development, Michael excels at integrating physical and polymer science insights into practical pharmaceutical development strategies. His comprehensive skill set, encompassing rheology, adhesion, and physical chemistry, enables him to drive forward cutting-edge research and translate scientific insights into impactful clinical applications, reinforcing Novartis’ position as a leader in drug delivery innovation.